What is this?
cGMP Raman and FTIR are vibrational spectroscopy methods used for chemical fingerprinting, raw-material identification, form differentiation, contaminant ID, and mixture or mapping applications.


Use vibrational spectroscopy for identity, solid-form differentiation, raw-material ID, mapping, contaminant analysis, and method development.
For cGMP work, method choice has to follow the quality attribute, sample matrix, method status, documentation need, and regulatory decision. The testing plan should connect method development, validation, method transfer, release testing, CoA support, and documentation requirements rather than treating each instrument run as an isolated activity.
cGMP Raman and FTIR are vibrational spectroscopy methods used for chemical fingerprinting, raw-material identification, form differentiation, contaminant ID, and mixture or mapping applications.
Use Raman/FTIR when the quality question can be answered by molecular vibrations, spatial location, polymorph discrimination, component mapping, or a validated raw-material ID method.
Spectra can be affected by fluorescence, water, particle size, orientation, matrix overlap, laser damage, pressure/contact artifacts, baseline correction, and spectral pre-processing choices.
Amounts may be very small for ID, but method validation, calibration, detection-limit, mixture, and mapping studies require representative standards and matrix controls.
XRPD, NMR, HPLC/GC, MS, microscopy, SEM/EDX, DSC/TGA, and particle methods compete or complement Raman/FTIR depending on the sample and decision.
FDA cares that the method is scientifically justified, specific for the intended attribute in the real matrix, controlled under the quality system, validated or verified where appropriate, data-integrity compliant, and lifecycle managed.
Common mistakes include using exploratory data as release evidence, validating the wrong matrix, ignoring sample preparation, under-documenting controls, relying on one technique when orthogonal evidence is needed, or failing to define the decision before testing.
Triclinic uses cGMP Raman and FTIR for regulated identity, material-comparison, contaminant, polymorph, and functional-group questions where spectral evidence must be collected and reviewed under controlled procedures. Real-world applications include raw-material identity support, release and stability testing, foreign-particle or residue investigations, and validated or verified methods that provide rapid orthogonal evidence for quality decisions.
Exploratory data can help choose a method, but release or filing-support data require controlled execution. The method must be suitable for the matrix, the quality attribute must be defined, reference standards and controls must be appropriate, and the report or CoA must say only what the data support.
| cGMP concern | Why it matters | Practical control |
|---|---|---|
| Method status | Exploratory, verified compendial, validated custom, and transferred methods have different evidence requirements. | Define status before testing and document any development, verification, validation, or transfer work. |
| Sample matrix | Specificity can fail in real drug product, excipient, talc, low-dose, or complex solid mixtures. | Use representative material, placebo/matrix controls, spike studies, or orthogonal methods where needed. |
| Data integrity | Release or stability results must survive QA review, audit, and regulatory scrutiny. | Use controlled records, system suitability, analyst review, deviations/OOS process, and traceable calculations. |
The table below lists the specific platforms, brands, models, software, detectors, and capability notes relevant to this cGMP service area.
| Instrument or platform | Brand, model, software, or detector | Additional capabilities and use |
|---|---|---|
| Dispersive Raman microscopy | Renishaw inVia Raman microscope with DMLM Leica microscope, 785 nm laser, and CCD detector | Chemical imaging, confocal microsampling, polymorph discrimination, carbon-nanotube characterization, and spatial component mapping. |
| FT-Raman | Thermo NXT FT-Raman module interfaced to Nicolet 6700 FT-IR spectrometer; 1064 nm Nd:YAG laser; InGaAs detector; OMNIC v.9.7.46 with spectral libraries | Micro and macro Raman sampling, reduced fluorescence for selected samples, library matching, and non-destructive molecular fingerprinting. |
| Low-frequency Raman | Ondax THz-Raman system with probe | Stokes and anti-Stokes signals from +/-5 cm-1 to 200 cm-1, or 150 GHz to 6 THz, for lattice-mode/polymorph-sensitive measurements. |
| Infrared imaging | Thermo iN10 MX with Picta 1.5.141 software | IR chemical imaging, ATR/reflection/transmission sampling, microsampling, real-time particle identification, and distribution mapping. |
| FT-IR | Thermo iS50 Model 60825 and Nicolet 6700; ATR, diffuse reflectance, transmission, gas cell; DTGS detector; OMNIC v.9.7.46 software | Functional-group identification, spectral-library matching, gas-cell/TGA-IR evolved-gas analysis, and organic/inorganic material identification. |
This example shows how vibrational spectroscopy can move from qualitative identification to spatially resolved product understanding. Raman and FTIR methods can support molecular fingerprinting, polymorph differentiation, raw-material identity, contaminant identification, and chemical imaging, but for cGMP use the spectral method must be specific for the matrix and validated, verified, or transferred for the decision it supports.

These examples cite Triclinic source documents, regulatory guidances, or literature relevant to this cGMP service. Download buttons are positioned at the bottom-left of each example.
Author: Triclinic Labs
Publication date: 2019
Abstract: This white paper describes how low-frequency Raman can distinguish polymorphic forms through lattice-mode information, making Raman an important orthogonal method for form ID and cGMP solid-mixture method development.
Author: Triclinic Labs
Publication date: April 2023
Abstract: This application note combines dissolution, PXRD, and low-frequency Raman mapping to connect chemical identity, phase, and spatial distribution in formulation-relevant samples.
Author: International Council for Harmonisation / FDA
Publication date: 2024
Abstract: These harmonized guidances describe validation and development principles for analytical procedures used to assess drug-substance and drug-product quality. They anchor expectations for specificity, accuracy, precision, range, robustness, lifecycle management, and fit-for-purpose method evidence in cGMP work.
Use cGMP NMR for identity, purity, qNMR, reference-material verification, method development, validation, and release testing.
View serviceUse cGMP XRPD for solid-form identification, polymorph or phase quantitation, crystallinity, method validation, release, and stability support.
View serviceDevelop, validate, verify, and transfer wet or dry particle-size methods for release specifications and quality decisions.
View serviceUse cGMP DSC and TGA to evaluate melting, desolvation, dehydration, glass transitions, degradation, and thermal material control.
View serviceUse cGMP microscopy and particle morphology evidence for identification, particle shape, foreign-material work, and regulated investigations.
View serviceUse verified or validated methods to support batch disposition, CoA issuance, stability testing, and regulatory documentation.
View serviceRun the work under cGMP when the result will support release, stability, regulatory documentation, method validation or transfer, CoA issuance, or a quality investigation rather than exploratory screening only.
Material requirements depend on method, matrix, replicate design, standards, destructive testing, retain needs, and whether method development, validation, transfer, or release testing is required. Confirm exact amounts before shipment.
Yes. The project should be scoped from the quality attribute, sample matrix, method status, and regulatory decision before selecting a technique or validation plan.
Defensible cGMP results require appropriate method status, sample traceability, reference standards, controls, system suitability, analyst training, data review, and clear reporting of limitations.
Yes. Triclinic develops, validates, and transfers Raman, FTIR, ATR-FTIR, infrared-imaging, and Raman-mapping methods when spectral identity, polymorph discrimination, component distribution, contaminant identification, or release/stability decisions require controlled execution. Method work can include laser or optical configuration, spectral range, sample preparation, reference libraries, mapping parameters, specificity, chemometrics, precision, robustness, and transfer controls.
Yes. Identity methods can be developed, verified, validated, or transferred when reference materials, spectral ranges, preprocessing, acceptance criteria, instrument configuration, sampling, and matrix or packaging effects are appropriately controlled.
Send the sample type, intended use of the data, method or monograph if available, specification, matrix, timeline, and whether the work is exploratory, cGMP, validation, transfer, stability, release, or investigation support.